TY - JOUR T1 - Killer Immunoglobulin-like Receptors and Tumor Immunity JF - Cancer Immunology Research JO - Cancer Immunol Res SP - 99 LP - 104 DO - 10.1158/2326-6066.CIR-13-0219 VL - 2 IS - 2 AU - Benson, Don M. AU - Caligiuri, Michael A. Y1 - 2014/02/01 UR - http://cancerimmunolres.aacrjournals.org/content/2/2/99.abstract N2 - Natural killer (NK) cells, large granular lymphocytes comprising a key cellular subset of innate immunity, were originally named for their capacity to elicit potent cytotoxicity against tumor cells independent of prior sensitization or gene rearrangement. This process is facilitated through the expression of activating and inhibitory receptors that provide for NK cell “education” and a subsequent ability to survey, recognize, and lyse infected or transformed cells, especially those lacking or possessing mutated MHC class I expression. Since these original observations were made, how NK cells recognize candidate target cells continues to be the topic of ongoing investigation. It is now appreciated that NK cells express a diverse repertoire of activating and inhibitory receptors of which killer immunoglobulin-like receptors (KIR) appear to play a critical role in mediating self-tolerance as well as facilitating cytotoxicity against infected or transformed cells. In addition, in the presence of an activating signal, the absence or mismatch of MHC class I molecules on such targets (which serve as inhibitory KIR ligands) promotes NK cell–mediated lysis. An increasing understanding of the complexities of KIR biology has provided recent opportunities to leverage the NK cell versus tumor effect as a novel avenue of immunotherapy for cancer. The present review summarizes the current understanding of KIR expression and function and highlights ongoing efforts to translate these discoveries into novel NK cell–mediated immunotherapies for cancer. Cancer Immunol Res; 2(2); 99–104. ©2014 AACR. ER -